A long term, 50 week, Phase IV multi-centre study to determine if Sati
A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- N/A
What it measured
Main measures
The primary endpoint is the change in cognitive function as assessed by the total Paced Auditory Serial Addition Test (PASAT I and II) score
Thinking and memory
Other measures (1)
To evaluate the efficacy of Sativex compared with placebo on:
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: Inclusion: Subjects meeting the following criteria will be considered eligible for this study. Exclusion: Exclusion: The subject may not enter the study if ANY of the following
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To compare the change in cognitive performance and psychological
Loading reviews and guidelines…
History
Started
May 2011